Corporate Banner
Satellite Banner
Biomolecular Screening
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Plexpress and MediSapiens Launch OncoTRAC™ Gene Expression Service

Published: Tuesday, October 02, 2012
Last Updated: Tuesday, October 02, 2012
Bookmark and Share
Digital gene discovery integrated with targeted validation and in-depth analysis.

The companies have launched the new OncoTRAC™ Gene Expression Service, which takes advantage of MediSapiens’ extensive IST Online Gene Expression Database to facilitate the rapid, reliable identification of relevant genes of interest. After this initial discovery phase, the Plexpress FAST TRAC Gene Expression Analysis technology is used to assay the expression of a hand-selected 30-gene panel in a large number of samples.  The unique combination of these two complimentary approaches presents a complete solution from gene discovery through to validation and in-depth study, across a wide range of drug development, biomarker discovery and life science research applications.

Tommi Pisto, CEO of MediSapiens, commented: “With a database of over 20,000 samples and 300 million data points, our MediSapiens IST Online Gene Expression Viewer is the world’s largest unified gene expression database. The new OncoTRAC Service will allow users to leverage this data to discover new genes and then investigate their biological relevance.” Visualizing a gene’s function across all tissues and exploring relationships between expression and disease, the database allows the straightforward integration of proprietary data, whilst strict normalization also allows the comparison of results from a wide spectrum of studies. Exploration and identification of the most relevant genes of interest from a pool of samples of various cancer types, treatment-response and disease grades are subsequently compared with expression in healthy tissue, providing a knowledge-based discovery approach.

CEO of Plexpress, Dr Jari Rautio, said: “TRAC is the ideal technology for following up genomic discovery using the IST Online Gene Expression Viewer, as it allows the multiplex analysis of up to 30 genes in hundreds to thousands of samples. In this way, researchers can really investigate the biology of their system in considerable depth, without sacrificing the number of genes they can assay in each sample.” The other benefits of the fully automatable TRAC process include increased assay speed, as well as reduced technical variation, hands-on time and assay cost when compared with similar methods such as qPCR and microarray analysis. While TRAC offers the flexibility to create custom gene panels, pre-validated catalogue libraries are also available for specific applications such as ADME-Tox studies, ready for rapid, ‘off-the-shelf’ utilization.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,000+ scientific posters on ePosters
  • More than 4,400+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Plexpress Announces Collaboration with Admescope
CRO to offer TRAC gene expression analysis for pre-clinical ADME-Tox studies.
Thursday, May 17, 2012
Plexpress Secures $2.3M to Commercialize TRAC High-Content Gene Expression Analysis Platform
Company targets applications including companion diagnostics and ADMET.
Thursday, April 19, 2012
Scientific News
Potential “Good Fat” Biomarker
New method to measure the activity of energy consuming brown fat cells could ease the testing weight loss drugs.
MicroRNA Pathway Could Lead to New Avenues for Leukemia Treatment
Cancer researchers at the University of Cincinnati have found a particular signaling route in microRNA (miR-22) that could lead to targets for acute myeloid leukemia, the most common type of fast-growing cancer of the blood and bone marrow.
Soy Shows Promise as Natural Anti-Microbial Agent
Soy isoflavones and peptides may inhibit the growth of microbial pathogens that cause food-borne illnesses, according to a new study from University of Guelph researchers.
Doubling Down on Dengue
HMS researchers have discovered two ways a compound blocks dengue virus.
Soy Shows Promise as Natural Anti-Microbial Agent
Researchers from University of Guelph show that soy isoflavones and peptides could be used to reduce microbial contamination of food.
AstraZeneca to Sequence 2 Million Genomes in Search for New Drugs
Company launches integrated genomics approach which aims to transform drug discovery and development.
Unique Model for Studying ALS
Unique mouse model will allow researchers to better study the genetic origins and potential treatments of ALS.
Targeting an ‘Undruggable’ Cancer Gene
RAS genes are mutated in more than 30 percent of human cancers and represent one of the most sought-after cancer targets for drug developers.
Biomarkers for Profiling Prostate Cancer Patients
Exiqon A/S has announced the publication of validation of prognostic microRNA biomarkers for the aggressiveness of prostate cancer in independent cohorts.
Improving Engineered T-Cell Cancer Treatment
Purdue University researchers may have figured out a way to call off a cancer cell assassin that sometimes goes rogue and assign it a larger tumor-specific "hit list."
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,400+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!